// App-Quantinova.ai

P494 : A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.

Researchers

Presenter

  • Radford-Smith, D

Principal Investigators

  • Satsangi, J

  • Louis, E

  • Laharie, D

  • Ding, N

  • Siegmund, B

  • D'Haens, G

  • Erik, H

  • Yates, A

  • Anthony, D

  • Colombel, J.F

  • Probert, F

Medical Centers

  • University of Oxford, Department of Oncology, Oxford, United Kingdom

  • University of Oxford, TGU, Nuffield Dept of Medicine, Oxford, United Kingdom

  • Ghent University Hospital, Department of Gastroenterology, Ghent, Belgium

  • Centre Hospitalier Universitaire CHU de Bordeaux, Service d'Hépato-gastroentérologie, Bordeaux, France

  • Imperial College London, Faculty of Medicine- Department of Surgery & Cancer, London, United Kingdom

  • Charite Universitaetsmedizin Berlin, Medical Oncology, Berlin, Germany

  • Amsterdam University Medical Centers, University of Amsterdam, Department of Intensive Care, Amsterdam, Netherlands

  • Skane University Hospital, Dep of Gastroenterology, Lund, Sweden

  • University of Oxford, Oxford, United Kingdom

  • Icahn School of Medicine at Mount Sinai, Department of Health Evidence and Policy, New York, United States

  • GETAID and the SPARE-Biocycle research group

Locations

  • United Kingdom

  • Belgium

  • France

  • Germany

  • Netherlands

  • Sweden

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • C reactive protein

  • Vasoactive intestinal polypeptide

Drug/Treatment

  • Infliximab

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved